Nexalin Technology Inc
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Stock Performance Snapshot
Financial Health
Nexalin Technology is earning modest revenue and profit margins, but overall performance is average.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NXL
Brain-Computer Interface
This collection features pioneering companies creating revolutionary pathways between the human brain and machines. These carefully selected stocks represent the cutting edge of neural technology, with potential to transform healthcare and computing through innovative brain signal interpretation.
Published: June 17, 2025
Explore BasketRest & Recharge
Tap into the booming wellness economy with companies revolutionizing how we sleep and relax. These carefully selected stocks represent innovative leaders in sleep technology, relaxation services, and wellness solutions that are responding to our growing desire for better rest and recovery.
Published: June 17, 2025
Explore BasketMental Wellness Portfolio
Invest in the future of mental healthcare. These carefully selected companies are leveraging technology to make mental health treatment more accessible, personalized, and effective, creating significant growth opportunities in an expanding market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Technology focus
Develops non‑invasive neurostimulation aimed at mental‑health and sleep conditions; clinical results will be central, though outcomes can vary.
Outcome-dependent upside
Successful trials and approvals could drive growth, but potential returns are balanced by regulatory, competitive and commercial execution risks.
Small‑cap dynamics
With a market cap around $28m, expect low liquidity and higher volatility; dilution from future funding is a common risk for early-stage stocks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
